Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Conmed (CNMD) Shares Repurchased (2010 - 2026)

Conmed posted quarterly Shares Repurchased of $37.0 million for Q1 2026, up 119.53% on a QoQ basis from $16.9 million in Q1 2014.

Conmed (CNMD) has 6 years of Shares Repurchased data on file, last reported at $37.0 million in Q1 2026.

For the quarter ending Q1 2026, Shares Repurchased changed N/A year-over-year to $37.0 million; the trailing twelve-month figure through Mar 2026 stood at $37.0 million (changed N/A YoY), and the FY2014 full-year result was $16.9 million, down 66.65% from the prior year.
Shares Repurchased for Q1 2026 stood at $37.0 million, up from $16.9 million in the prior quarter.
Across five years, Shares Repurchased topped out at $37.0 million in Q1 2026 and bottomed at $37.0 million in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Shares Repurchased (Qtr)
1	Abbott Laboratories	152.82 Bn	146.17 Bn	6.27 Bn	180.00 Mn
2	Stryker	115.07 Bn	112.19 Bn	3.81 Bn	-
3	Medtronic	95.25 Bn	87.08 Bn	5.76 Bn	105.00 Mn
4	Boston Scientific	71.38 Bn	70.17 Bn	3.61 Bn	-
5	Edwards Lifesciences	51.08 Bn	47.41 Bn	1.29 Bn	421.80 Mn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-
7	Dexcom	28.84 Bn	27.72 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.56 Bn	26.49 Bn	1.98 Bn	100.00 Mn
9	Steris	20.71 Bn	20.30 Bn	697.10 Mn	74.30 Mn
10	Conmed	1.06 Bn	1.02 Bn	183.45 Mn	37.02 Mn

Historic Data

Download Data 🔒

Date	Value
Mar 31, 2026	37.02 Mn
Mar 31, 2026	37.02 Mn
Mar 31, 2014	16.86 Mn
Mar 31, 2014	16.86 Mn
Dec 31, 2013	5.83 Mn
Dec 31, 2013	5.83 Mn
Jun 30, 2013	19.00 Mn
Jun 30, 2013	19.00 Mn
Mar 31, 2013	25.73 Mn
Mar 31, 2013	25.73 Mn
Dec 31, 2012	3.92 Mn
Dec 31, 2012	3.92 Mn
Sep 30, 2011	15.02 Mn
Sep 30, 2011	15.02 Mn
Sep 30, 2010	32.45 Mn
Sep 30, 2010	32.45 Mn